sprite-preloader
Samstag, 29.04.2017 Börsentäglich über 12.000 News von 563 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrTakeda picks up FDA approval for Alunbrig, a potential blockbuster
FrMerck's Vytorin set for massive sales slide as generics hit
FrNovartis wins FDA nod for Rydapt, new targeted drug for AML
FrAstraZeneca investors rebel against CEO's 2016 pay hike
FrSanofi enjoys solid Q1, despite continuing erosion of Lantus sales in U.S.
FrBayer gets Stivarga-Nexavar bridge in liver cancer
DoBioMarin picks up FDA nod for orphan drug Brineura
DoAs SCOTUS steps into biosim tangle, experts weigh in
DoResurgent Humira powers AbbVie to Q1 beat
DoThought Opdivo was down and out? Think again, Bristol says with Q1 beats
DoNovartis to pay $50M in Korean bribery probe
DoDaiichi Sankyo to beef up ADC production with $135M investment in Japan
DoCost cuts, castoffs help AstraZeneca power past Q1 forecast
DoRegeneron tax rate highest, Amgen lowest in U.S. biopharma
DoFiercePharma's 2017 first-quarter earnings roundup
DoChina's new foreign drug proposal: Pharmas excited, analysts cautious
MiRegeneron CEO pay sinks, but still tops $28M
MiAmgen, Sandoz argue biosimilars case before Supreme Court
MiTeva eyes debt-cutting sale of its cancer meds: report
MiGSK's new CEO stands by three-unit structure amid 'quiet' Q1 results
MiAAN rundown, with dueling MS data, new candidates and more
MiNeurocrine goes high-$60K-plus high-with Ingrezza price
MiArt imitates migraine? Allergan's asking sufferers to try
MiJ&J, Bayer face first jury trial over Xarelto's bleedings risks
MiJ&J, Novartis, Takeda eye stake in Brazil's Hypermarcas